Wist u dat uw browser verouderd is?

Om de best mogelijke gebruikerservaring van onze website te krijgen raden wij u aan om uw browser te upgraden naar een nieuwere versie of een andere browser. Klik op de upgrade button om naar de download pagina te gaan.

Upgrade hier uw browser
Ga verder op eigen risico

Ofipharma/Ofichem secures the Netherlands with extra Propofol supply

Ofipharma and Ofichem have managed to bring in additional stock of Propofol ampoules to the Netherlands, thanks to their global network and the unique collaboration between the Ministry of Health (VWS) and the National Medicines Coordination Centre (LCG). As such they were able to make an important contribution in securing the availability of this medicine for Dutch ICUs. Propofol is an essential anaesthetic in the ventilation of COVID-19 patients.

The shipment from South Korea is being delivered to the Netherlands in three stages; the first 2 of these arrived at Schiphol this weekend. The extra stock was secured thanks to the efforts of the National Medicines Coordination Centre (LCG), the Ministry of Health, Welfare and Sport and wholesaler, Ofipharma/Ofichem.

During the corona crisis, Propofol is also being used for COVID-19 patients who need to be ventilated in intensive care. As COVID-19 patients will often need to be ventilated for weeks, stocks of Propofol are under pressure worldwide. Just last week, the LCG called on hospitals to adopt a Propofol-sparing policy.

“Over the past few weeks, together with the Ministry of Health, Welfare and Sport and wholesaler Ofipharma/ Ofichem, we have been working hard to bring this Propofol to the Netherlands,” says Joris Uges, Chairman of the National Medicines Coordination Centre. “With this extra stock, we can continue our care for the time being but vigilance is still required and we call on the hospitals to use it as sparingly as possible.”

According to Ofipharma Director, Jeroen Gordijn, it was not easy to bring the stock to the Netherlands. “Many other countries are also chasing these products and there is a limit to the number of reliable suppliers,” says Gordijn. “Partly due to good contacts on the spot, we finally succeeded.”